Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 12/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 11/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1416325 | 0.79 | IDO1 (0.45) | METAP2KDM1A | |
| SCHEMBL1416022 | 0.79 | IDO1 (0.45) | KDM1ACYP19A1MAP4K4 | |
| SCHEMBL1416170 | 0.79 | HPGDS (0.45) | MAP4K4 | |
| SCHEMBL6374850 | 0.79 | NPC1 (0.46) | CYP3A4METAP2MAP4K4 | |
| SCHEMBL4781592 | 0.77 | MAPT (0.43) | KDM1ACYP19A1 | |
| SCHEMBL69777 | 0.77 | KMT2A (0.41) | CYP3A4METAP2 | |
| SCHEMBL1201626 | 0.76 | CLK4 (0.53) | KDM1A | |
| SCHEMBL16719476 | 0.76 | HSD17B1 (0.61) | HSD17B1HSD17B2CYP3A4CYP2C9METAP2 | |
| SCHEMBL4275454 | 0.75 | HSD17B1 (0.56) | HSD17B1HSD17B2CYP3A4CYP2C9METAP2 | |
| SCHEMBL1416518 | 0.75 | CLK4 (0.51) | CYP3A4CYP2C9KDM1ACYP19A1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | claimed |
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| CN-105392777-A | Biaryl derivatives as GRP120 agonists | LG LIFE SCIENCES LTD | 2016-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | HSD17B1 339/4885HSD17B2 229/4885CYP3A4 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.